Titan Pharmaceuticals Inc. (TTNP)
-OTC BB 0.54 
0.01(1.64%) 9:59AM EDT
| Prev Close: | 0.55 |
|---|
| Open: | 0.55 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 2.50 |
|---|
| Beta: | 2 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.54 - 0.55 |
|---|
| 52wk Range: | 0.32 - 2.53 |
|---|
| Volume: | 45,070 |
|---|
| Avg Vol (3m): | 1,456,420 |
|---|
| Market Cap: | 44.57M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.06 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- TITAN PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- TITAN PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Titan Pharma upgraded by Brinson PatrickBriefing.com(Thu, May 16)
- Titan Pharmaceuticals Announces First Quarter 2013 Financial ResultsMarketwired(Wed, May 15)
- TITAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2013 Financial ResultsMarketwired(Thu, May 9)
- Looking For Opportunity - 5 Biotechs That Crashedat Seeking Alpha(Mon, May 6)
- Titan Plunges After FDA Rejects Drug-Addiction Treatmentat Bloomberg(Wed, May 1)
- FDA Rejection Of Probuphine Hits Titan Hardat Seeking Alpha(Wed, May 1)
- FDA Rejection of Titan's Probuphine Looks Like a Muggingat TheStreet(Wed, May 1)
- UPDATE 1-FDA rejects Titan drug for opioid dependenceat Reuters(Wed, May 1)
- FDA Rejects Titan Pharma's Opioid Addiction Implant Probuphineat Seeking Alpha(Wed, May 1)
- Titan Pharmaceuticals Receives Complete Response Letter From the FDA for Probuphine New Drug ApplicationMarketwired(Tue, Apr 30)
- Titan Pharma Approaches Expected FDA Approvalat Seeking Alpha(Tue, Apr 23)
- Titan Pharmaceuticals' Probuphine Program to Be Presented at ASAM Medical-Scientific Conference and APA Annual MeetingMarketwired(Mon, Apr 22)
Key Statistics
| Forward P/E (1 yr): | 3.38 |
|---|
| P/S (ttm): | 4.11 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.03 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Titan Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing proprietary therapeutics for the treatment of serious medical disorders in the United States.
View More